Diseases /
Breast Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla. [1]
Biomarker-Directed Therapies
Of the biomarker-directed therapies for breast carcinoma, 29 are FDA-approved in at least one setting and 30 have NCCN guidelines in at least one setting [3].
Abemaciclib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. |
Ado-Trastuzumab Emtansine +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated (as a single agent) for the treatment of patients with HER2+ positive breast cancer in either the adjuvant or metastatic setting who previously received trastuzumab and a taxane, separately or in combination. |
Anastrozole +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for locally advanced or metastatic breast cancer as first-line treatment or after progression on tamoxifen. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (NICE, SMC) |
| Note: Please note that NICE guidance stipulates estrogen receptor (ER) expression as the criterion for primary adjuvant therapy with anastrozole, not progesterone receptor (PR). |
Bicalutamide +
Everolimus +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (BNF) |
Exemestane +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for metastatic disease. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (BNF) |
Fam-Trastuzumab Deruxtecan +
Disease is predicted to be sensitive: -
Fulvestrant +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for HR-positive, HER2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, and for HR-positive advanced disease with progression following endocrine therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (BNF) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (SMC) |
Lapatinib +
Letrozole +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for advanced breast cancer as first-line treatment or after progression following antiestrogen therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Neoadjuvant (BNF) |
Margetuximab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated in combination with chemotherapy for metastatic HER2-positive breast cancer that received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. |
Neratinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HER2-positive breast cancer, both in combination with capecitabine for advanced or metastatic disease with two or more prior anti-HER2 based regimens in the metastatic setting, and as a single agent for extended adjuvant treatment following adjuvant trastuzumab-based therapy. |
Olaparib +
Disease is predicted to be sensitive: -
Pembrolizumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) >= 10]. |
Pertuzumab +
Pertuzumab/trastuzumab/hyaluronidase +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, pertuzumab/trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab + pertuzumab in any regimen. |
Sacituzumab Govitecan +
Disease is predicted to be sensitive: -
Talazoparib +
Disease is predicted to be sensitive: -
Tamoxifen +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HR+ breast cancer, both as adjuvant treatment and in the metastatic setting. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NICE) |
Toremifene +
Disease is predicted to be sensitive: -
Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HER2-overexpressing breast cancer: (1) for metastatic disease with paclitaxel as first-line treatment, and as a single agent after one or more chemotherapy regimens. NCCN recommended with various chemotherapy combinations. (2) for adjuvant treatment with chemotherapy and as a single agent following multi-modality anthracycline based therapy. (3) Also NCCN recommended for neoadjuvant treatment. |
Trastuzumab/hyaluronidase +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab in any regimen. |
Abemaciclib + Aromatase Inhibitor +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. |
Abemaciclib + Fulvestrant +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Ado-Trastuzumab Emtansine + Endocrine Therapy +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Adjuvant (NCCN) |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer. |
Alpelisib + Fulvestrant +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: PIK3CA E545Q, PIK3CA Q546K, PIK3CA Q546P, PIK3CA E365K, PIK3CA E453K, PIK3CA G1049R, PIK3CA G106V, PIK3CA G118D, PIK3CA K111E, PIK3CA K111N, PIK3CA M1043I, PIK3CA M1043V, PIK3CA N345K, PIK3CA P447_L455del, PIK3CA P539R, PIK3CA R108H, PIK3CA R88Q, PIK3CA R93W, PIK3CA T1025A, PIK3CA V344G, PIK3CA V344M Sample must match all of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for HR-positive, HER2-negative, PIK3CA-mutated, recurrent or metastatic breast cancer. |
Anastrozole + Fulvestrant +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as first line therapy. |
Aromatase Inhibitor + Lapatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: FDA approved with letrozole as the aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. NCCN recommended for any aromatase inhibitor. |
Aromatase Inhibitor + Lapatinib + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for HR-positve/HER2-positive recurrent or metastastic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in postmenopausal women or in men. |
Aromatase Inhibitor + Ribociclib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. |
Aromatase Inhibitor + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (SMC) |
Atezolizumab + Nab-Paclitaxel +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area. |
Capecitabine + Lapatinib +
Disease is predicted to be sensitive: -
Capecitabine + Trastuzumab + Tucatinib +
Disease is predicted to be sensitive: -
Carboplatin + Docetaxel + Trastuzumab +
Docetaxel + Trastuzumab +
Endocrine Therapy + Pertuzumab + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Adjuvant (NCCN) |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer, with or without chemotherapy. |
Endocrine Therapy + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) |
| Note: Recommend for HR-positive/HER2-positive breast cancer, with fulvestrant, tamoxifen, or aromatase inhibitor metastastic disease, or with tamoxifen or aromatase inhibitor for adjuvant treatment. |
Everolimus + Exemestane +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for postmenopausal women with advanced HR+, HER2- breast cancer after failure of treatment with letrozole or anastrozole. |
Everolimus + Fulvestrant +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as subsequent line therapy. |
Everolimus + Tamoxifen +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as subsequent line therapy. |
Fulvestrant + Letrozole +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as first line therapy. |
Fulvestrant + Palbociclib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Fulvestrant + Ribociclib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy, or following disease progression on endocrine therapy. |
Lapatinib + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommened for recurrent or metastatic HER2-positive breast cancer, without cytotoxic therapy. |
Paclitaxel + Pertuzumab + Trastuzumab +
Paclitaxel + Trastuzumab +
Pertuzumab + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: FDA approved for HER2-positive breast cancer, for metastatic disease with paclitaxel for with no prior anti-HER2 therapy or chemotherapy in that setting, and for adjuvant and neoadjuvant treatment in combination with chemotherapy. Per NCCN, other chemotherapy combinations, or no chemotherapy combination, are options for these settings. |
Clinical Trials
There are 1300 clinical trials for breast carcinoma, of which 880 are open and 420 are completed or closed. Of the trials that contain breast carcinoma as an inclusion criterion, 20 are early phase 1 (12 open), 379 are phase 1 (231 open), 219 are phase 1/phase 2 (160 open), 483 are phase 2 (325 open), 12 are phase 2/phase 3 (8 open), 134 are phase 3 (106 open), 8 are phase 4 (3 open), and 45 are no phase specified (35 open).
HER2, ER, and PR are the most frequent gene inclusion criteria for breast carcinoma clinical trials [3].
Trastuzumab, paclitaxel, and pembrolizumab are the most common interventions in breast carcinoma clinical trials.
Significant Genes in Breast Carcinoma
ABL2 +
ABL2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ACVR1B +
ACVR1B is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
AKT1 +
AKT1 is an inclusion eligibility criterion in 10 clinical trials for breast carcinoma, of which 9 are open and 1 is closed. Of the trials that contain AKT1 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
AKT2 +
AKT2 is an inclusion eligibility criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain AKT2 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
AKT3 +
AKT3 is an inclusion eligibility criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain AKT3 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
ALK +
ALK is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [3].
APC +
APC is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
APH1A +
APH1A is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain APH1A status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
APOBEC3B +
APOBEC3B is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3B status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ARAF +
ARAF is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ARID1A +
ARID1A is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ARID1A status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
ASXL1 +
ASXL1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 26 clinical trials for breast carcinoma, of which 21 are open and 5 are closed. Of the trials that contain ATM status and breast carcinoma as inclusion criteria, 7 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 13 are phase 2 (11 open), and 2 are phase 3 (2 open) [3].
ATR +
ATR is an inclusion eligibility criterion in 22 clinical trials for breast carcinoma, of which 17 are open and 5 are closed. Of the trials that contain ATR status and breast carcinoma as inclusion criteria, 7 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
ATRX +
ATRX is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATRX status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
BACH1 +
BACH1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BACH1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BAP1 +
BAP1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 23 clinical trials for breast carcinoma, of which 19 are open and 4 are closed. Of the trials that contain BARD1 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [3].
BCL2 +
BCL2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BCL6 +
BCL6 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BLM +
BLM is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BLM status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
BRAF +
BRAF is an inclusion eligibility criterion in 8 clinical trials for breast carcinoma, of which 6 are open and 2 are closed. Of the trials that contain BRAF status and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [3].
BRCA1 +
BRCA1 is an inclusion eligibility criterion in 70 clinical trials for breast carcinoma, of which 54 are open and 16 are closed. Of the trials that contain BRCA1 status and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 16 are phase 1 (10 open), 10 are phase 1/phase 2 (8 open), 32 are phase 2 (25 open), 1 is phase 2/phase 3 (1 open), 9 are phase 3 (8 open), and 1 is phase 4 (1 open) [3].
Olaparib and talazoparib have evidence of efficacy in patients with BRCA1 mutation in breast carcinoma [3].
BRCA2 +
BRCA2 is an inclusion eligibility criterion in 70 clinical trials for breast carcinoma, of which 54 are open and 16 are closed. Of the trials that contain BRCA2 status and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 16 are phase 1 (10 open), 10 are phase 1/phase 2 (8 open), 32 are phase 2 (25 open), 1 is phase 2/phase 3 (1 open), 9 are phase 3 (8 open), and 1 is phase 4 (1 open) [3].
Olaparib and talazoparib have evidence of efficacy in patients with BRCA2 mutation in breast carcinoma [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 23 clinical trials for breast carcinoma, of which 19 are open and 4 are closed. Of the trials that contain BRIP1 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
C11ORF30 +
C11orf30 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain C11orf30 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
CCND1 +
CCND1 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 2 are open and 2 are closed. Of the trials that contain CCND1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [3].
CCND2 +
CCND2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
CCND3 +
CCND3 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CCND3 status and breast carcinoma as inclusion criteria, 2 are phase 2 (0 open) [3].
CCNE1 +
CCNE1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCNE1 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
CCNE2 +
CCNE2 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCNE2 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
CDK12 +
CDK12 is an inclusion eligibility criterion in 24 clinical trials for breast carcinoma, of which 19 are open and 5 are closed. Of the trials that contain CDK12 status and breast carcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [3].
CDK2 +
CDK2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
CDK4 +
CDK4 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 2 are open and 2 are closed. Of the trials that contain CDK4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain CDK6 status and breast carcinoma as inclusion criteria, 3 are phase 2 (1 open) [3].
CDKN1A +
CDKN1A is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1A status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
CDKN1B +
CDKN1B is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1B status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
CDKN2A +
CDKN2A is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 1 is open and 3 are closed. Of the trials that contain CDKN2A status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (1 open) [3].
CHD4 +
CHD4 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 22 clinical trials for breast carcinoma, of which 18 are open and 4 are closed. Of the trials that contain CHEK1 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 23 clinical trials for breast carcinoma, of which 19 are open and 4 are closed. Of the trials that contain CHEK2 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [3].
CRKL +
CRKL is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain CRKL status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CYLD +
CYLD is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DICER1 +
DICER1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DLL4 +
DLL4 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain DLL4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
DNMT3A +
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is an inclusion eligibility criterion in 11 clinical trials for breast carcinoma, of which 9 are open and 2 are closed. Of the trials that contain EGFR status and breast carcinoma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), and 6 are phase 2 (5 open) [3].
EPCAM +
EPCAM is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 285 clinical trials for breast carcinoma, of which 192 are open and 93 are closed. Of the trials that contain ERBB2 status and breast carcinoma as inclusion criteria, 2 are early phase 1 (1 open), 70 are phase 1 (37 open), 43 are phase 1/phase 2 (30 open), 119 are phase 2 (83 open), 2 are phase 2/phase 3 (0 open), 41 are phase 3 (33 open), and 8 are no phase specified (8 open) [3].
Ado-trastuzumab emtansine, trastuzumab, aromatase inhibitor, lapatinib, pertuzumab/trastuzumab/hyaluronidase, pertuzumab, paclitaxel, neratinib, margetuximab, fam-trastuzumab deruxtecan, endocrine therapy, docetaxel, carboplatin, capecitabine, tucatinib, and trastuzumab/hyaluronidase have evidence of efficacy in patients with ERBB2 mutation in breast carcinoma [3].
ERBB3 +
ERBB3 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC2 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
ERCC3 +
ERCC3 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC3 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
ERCC4 +
ERCC4 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC4 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
ERCC5 +
ERCC5 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC5 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
ERCC6 +
ERCC6 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC6 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
ESR1 +
ESR1 is an inclusion eligibility criterion in 8 clinical trials for breast carcinoma, of which 7 are open and 1 is closed. Of the trials that contain ESR1 status and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 6 are phase 2 (6 open) [3].
EXO1 +
EXO1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
FAN1 +
FAN1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FAN1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCA +
FANCA is an inclusion eligibility criterion in 23 clinical trials for breast carcinoma, of which 19 are open and 4 are closed. Of the trials that contain FANCA status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 13 are phase 2 (11 open), and 2 are phase 3 (2 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 20 clinical trials for breast carcinoma, of which 16 are open and 4 are closed. Of the trials that contain FANCB status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain FANCC status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain FANCD2 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain FANCE status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain FANCF status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
FANCG +
FANCG is an inclusion eligibility criterion in 20 clinical trials for breast carcinoma, of which 16 are open and 4 are closed. Of the trials that contain FANCG status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 20 clinical trials for breast carcinoma, of which 16 are open and 4 are closed. Of the trials that contain FANCI status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain FANCL status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [3].
FANCM +
FANCM is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain FANCM status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
FBXW7 +
FBXW7 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FBXW7 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 8 clinical trials for breast carcinoma, of which 7 are open and 1 is closed. Of the trials that contain FGFR1 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 4 are phase 2 (4 open) [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 9 clinical trials for breast carcinoma, of which 7 are open and 2 are closed. Of the trials that contain FGFR2 status and breast carcinoma as inclusion criteria, 5 are phase 1 (3 open) and 4 are phase 2 (4 open) [3].
FGFR3 +
FGFR3 is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FGFR3 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 2 are phase 2 (2 open) [3].
FGFR4 +
FGFR4 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR4 status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
FH +
FH is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FH status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT3 +
FLT3 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
GATA3 +
GATA3 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HDAC1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HDAC2 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
HGF +
HGF is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
HRAS +
HRAS is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain IDH1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [3].
IDH2 +
IDH2 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
JAG1 +
JAG1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain JAG1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KDM6A +
KDM6A is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KDM6A status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].
KDR +
KDR is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KEAP1 +
KEAP1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KEAP1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KIT +
KIT is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
KMT2C +
KMT2C is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KMT2D +
KMT2D is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KMT2D status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].
KRAS +
KRAS is an inclusion eligibility criterion in 10 clinical trials for breast carcinoma, of which 6 are open and 4 are closed. Of the trials that contain KRAS status and breast carcinoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (0 open) [3].
LRP5 +
LRP5 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
LRP6 +
LRP6 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAGI2 +
MAGI2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MAML1 +
MAML1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAML1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
MAP2K1 +
MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MAP2K2 +
MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MAP2K4 +
MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MAP3K1 +
MAP3K1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].
MAPK1 +
MAPK1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MCL1 +
MCL1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 15 clinical trials for breast carcinoma, of which 12 are open and 3 are closed. Of the trials that contain MCPH1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 2 are phase 3 (2 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain MDM2 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
MDM4 +
MDM4 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MDM4 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
MED12 +
MED12 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MET +
MET is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MET status and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [3].
MGMT +
MGMT is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MGMT status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLF1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
MLH1 +
MLH1 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH3 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 22 clinical trials for breast carcinoma, of which 18 are open and 4 are closed. Of the trials that contain MRE11A status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MSH2 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MSH3 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
MSH6 +
MSH6 is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MSH6 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
MST1R +
MST1R is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MTOR +
MTOR is an inclusion eligibility criterion in 8 clinical trials for breast carcinoma, of which 8 are open and 0 are closed. Of the trials that contain MTOR status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
MUTYH +
MUTYH is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MUTYH status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
MYC +
MYC is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MYC status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].
NBN +
NBN is an inclusion eligibility criterion in 23 clinical trials for breast carcinoma, of which 19 are open and 4 are closed. Of the trials that contain NBN status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 13 are phase 2 (11 open), and 2 are phase 3 (2 open) [3].
NCSTN +
NCSTN is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NCSTN status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
NF1 +
NF1 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
NF2 +
NF2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NFE2L2 +
NFE2L2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFE2L2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
NOTCH1 +
NOTCH1 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain NOTCH1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [3].
NOTCH2 +
NOTCH2 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain NOTCH2 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [3].
NOTCH3 +
NOTCH3 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NOTCH3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
NOTCH4 +
NOTCH4 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NOTCH4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
NRAS +
NRAS is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].
NRG1 +
NRG1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
NSD1 +
NSD1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NTRK1 +
NTRK1 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain NTRK1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NTRK2 status and breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].
NTRK3 +
NTRK3 is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NTRK3 status and breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].
NUTM1 +
NUTM1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain NUTM1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 26 clinical trials for breast carcinoma, of which 22 are open and 4 are closed. Of the trials that contain PALB2 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].
PARP1 +
PARP1 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PARP1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP2 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
PCNA +
PCNA is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 8 clinical trials for breast carcinoma, of which 8 are open and 0 are closed. Of the trials that contain PDGFRA status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
PDGFRB +
PDGFRB is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and breast carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
PIK3C2B +
PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CA +
PIK3CA is an inclusion eligibility criterion in 37 clinical trials for breast carcinoma, of which 29 are open and 8 are closed. Of the trials that contain PIK3CA status and breast carcinoma as inclusion criteria, 11 are phase 1 (6 open), 7 are phase 1/phase 2 (6 open), 15 are phase 2 (14 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (2 open) [3].
Alpelisib and fulvestrant have evidence of efficacy in patients with PIK3CA mutation in breast carcinoma [3].
PIK3CB +
PIK3CB is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 2 are open and 2 are closed. Of the trials that contain PIK3CB status and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].
PIK3CG +
PIK3CG is an inclusion eligibility criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PIK3CG status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
PIK3R1 +
PIK3R1 is an inclusion eligibility criterion in 8 clinical trials for breast carcinoma, of which 7 are open and 1 is closed. Of the trials that contain PIK3R1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
PIK3R2 +
PIK3R2 is an inclusion eligibility criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PIK3R2 status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PMS1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PMS2 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
POLD1 +
POLD1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
POLE +
POLE is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain POLE status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PPP2R1A status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PPP2R2A status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
PTCH1 +
PTCH1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PTEN +
PTEN is an inclusion eligibility criterion in 33 clinical trials for breast carcinoma, of which 27 are open and 6 are closed. Of the trials that contain PTEN status and breast carcinoma as inclusion criteria, 9 are phase 1 (6 open), 6 are phase 1/phase 2 (4 open), 15 are phase 2 (14 open), and 3 are phase 3 (3 open) [3].
PTGS2 +
PTGS2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTGS2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PTPN11 +
PTPN11 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain RAD50 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain RAD51 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 22 clinical trials for breast carcinoma, of which 18 are open and 4 are closed. Of the trials that contain RAD51B status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 25 clinical trials for breast carcinoma, of which 21 are open and 4 are closed. Of the trials that contain RAD51C status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 13 are phase 2 (11 open), and 2 are phase 3 (2 open) [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 24 clinical trials for breast carcinoma, of which 20 are open and 4 are closed. Of the trials that contain RAD51D status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [3].
RAD54L +
RAD54L is an inclusion eligibility criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain RAD54L status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [3].
RAF1 +
RAF1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAF1 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RB1 +
RB1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain RB1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
RET +
RET is an inclusion eligibility criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RFC1 +
RFC1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC2 +
RFC2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC3 +
RFC3 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC4 +
RFC4 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC5 +
RFC5 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain RICTOR status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
RNF43 +
RNF43 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
ROS1 +
ROS1 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
RPA1 +
RPA1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA2 +
RPA2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA3 +
RPA3 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA4 +
RPA4 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPTOR +
RPTOR is an inclusion eligibility criterion in 6 clinical trials for breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain RPTOR status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
RSPO1 +
RSPO1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RUNX1 +
RUNX1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SDHA +
SDHA is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHA status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SDHB +
SDHB is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SDHC +
SDHC is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHC status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SDHD +
SDHD is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SETD2 +
SETD2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SLC29A1 +
SLC29A1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLC29A1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 19 clinical trials for breast carcinoma, of which 15 are open and 4 are closed. Of the trials that contain SLX4 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (7 open), and 2 are phase 3 (2 open) [3].
SMARCA2 +
SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SMARCA4 +
SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain SMARCA4 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].
SMARCB1 +
SMARCB1 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain SMARCB1 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
SOX9 +
SOX9 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SRC +
SRC is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
SS18 +
SS18 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SS18 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SSBP1 +
SSBP1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
SSX1 +
SSX1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SSX2 +
SSX2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SSX2B +
SSX2B is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SSX4 +
SSX4 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
STAG2 +
STAG2 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain STAG2 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
STK11 +
STK11 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain STK11 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
TAF1 +
TAF1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TBX3 +
TBX3 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TET2 +
TET2 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TOP2A +
TOP2A is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TOP2A status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
TP53 +
TP53 is an inclusion eligibility criterion in 5 clinical trials for breast carcinoma, of which 1 is open and 4 are closed. Of the trials that contain TP53 status and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 2 are phase 2 (0 open) [3].
TSC1 +
TSC1 is an inclusion eligibility criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain TSC1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
TSC2 +
TSC2 is an inclusion eligibility criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain TSC2 status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
VEGFA +
VEGFA is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
VHL +
VHL is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
WNT1 +
WNT1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
WNT5A +
WNT5A is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains WNT5A status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
WRN +
WRN is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WRN status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XPO1 +
XPO1 is an inclusion eligibility criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
XRCC1 +
XRCC1 is an inclusion eligibility criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain XRCC1 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
